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Abstract
The study compares the cost-sharing (co-payment) arrangements for prescribed medicines
in a sample of EU countries. Through a set of typical prescription scenarios, the cost burden
to individual patients of prescriptions are examined, in the context of drug price, and from
the perspective of therapeutic need. The cost to patients of medicines is consistently lower in
some, and higher in other, countries, regardless of the type of prescription charge system.
Fixed charge systems, as opposed to graduated co-payment systems, are obviously more
likely to lead to similar charges for the treatment of comparable clinical conditions, but
depending on the level of the charge, can result in the patient paying a higher charge than
the price of the drug to the health organisation. Exemption from charges for prescription
medicines, commonly relate to clinical condition and level of income. Some systems also
have age-related criteria and apply ceilings to the total prescription cost burden borne by the
patient. The impact on patient costs of specific policy formulations is discussed and a
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proposal is made for cost convergence for comparable therapies. The method used in this
study may also provide a route for investigating model systems prior to implementation.
© 2000 Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
The cost of health care, and particularly the cost of prescription medicines,
present major challenges to public expenditure policies. EU Member states have
adopted a diverse range of approaches to cost-containment of pharmaceuticals on
both demand and supply sides. The prices of prescription medicines vary greatly
between countries, but policies common to most, are systems for cost sharing the
financial burden with consumers.
Burstall [1] argues that the purpose of prescription co-payments or charges is to
restrain public spending on medicines, and there is a considerable body of evidence,
particularly from the UK and USA, that shows the demand for prescription
medicines is reduced by a direct financial contribution from the patient [2]. It is
therefore important to formulate pharmaceutical reimbursement policies that do
not jeopardize patients’ needs.
Grootendorst [3] has shown that the onset of insurance cover for medicines was
associated with an increase in drug utilisation, concentrated among patients with
lower health status. Further, Stuart and Grana [4] in charting the impact of annual
income of an elderly population on their medication rates, have demonstrated those
in the lowest groups (B$6000) were 25% less likely to medicate a given health
problem than those in the top groups (\$18 000). EU Member States therefore
commonly have age and low income as grounds for exemption from cost-sharing
arrangements for prescription medicines.
Most evaluations of co-payment systems [5–10] have concentrated on overall
price elasticity, i.e. the impact of increases in patient contribution on the overall
uptake of prescription medicines. However, recently it has been shown that price
elasticity can vary markedly between different therapeutic groups of drugs [4,11],
raising concern about whether changes in cost-sharing arrangements affect the
uptake of both essential and non-essential drugs similarly [12]. Countries which
have adopted new co-payment systems more recently, have been particularly keen
to explore their impact on the uptake of essential medicines in the evaluation of
their systems [13,14]. Under the recently introduced Swedish system, some 20% of
households have attempted to attenuate the cost burden of prescription drugs. The
most commonly prescribed drugs where uptake was reduced by the implementation
of the new co-payment arrangements were those for asthma, allergy, pain, gas-
trointestinal ulcers and skin disorders. The greater the number of items prescribed,
the more marked the reduction in uptake. The scheme has had the greatest impact
on those on disability pensions or long-term sick leave, those with larger families
(three or four children), single parents, students and the unemployed [14].
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This study differs from previous ones exploring prescription charge or reimburse-
ment policies which have taken a system or population approach in a single country
or health insurance scheme. This international survey determines the cost of
prescribed medication at the level of the individual patient. The approach that has
been taken is to develop scenarios of hypothetical profiles of patients requiring drug
therapy for the treatment of common clinical conditions.
The purpose of the current study is to explore the cost to patients, in a sample
of EU member states, of prescribed medication with a view to identifying:
1. factors determining the patient costs of prescribed medication and whether any
trends are discernible between different types of cost-sharing schemes and:or
different countries;
2. the patient costs of comparable regimens of drug therapy;
3. means of reducing the prescription cost burden to patients
4. issues for consideration in the formulation of cost-sharing policies for prescrip-
tion medicines.
2. Methods
The first challenge was to select for study a variety of prescription charge plans
that reflected the diversity of systems within the EU. As a starting point, we selected
the countries in which members were based of an existing EU funded-network, the
Evaluation Network of Drug Expenditure and Policy (ENDEP), which included a
range of fixed charge and graduated payment systems, and a variety of exemption
and compensatory mechanisms. The patient charge systems in the following coun-
tries are described: Austria, Denmark, Finland, France, Germany, Italy, Nether-
lands and the UK.
To explore the impact of the various systems on the cost burden of prescribed
medication at the level of the individual patient, a set of 20 scenarios was devised
and piloted, each of which included a prescription for one or more products to treat
a common uncomplicated clinical condition — either acute, episodic or chronic.
The scenarios cover a typical range of domestic and social circumstances of patients
requiring treatment from primary care physicians. They do not include scenarios of
elderly patients, who commonly suffer from multiple pathologies that require more
complex drug regimens, and can be eligible for exemptions on a variety of grounds
— age, income, clinical conditions, or have reached ceilings for prescription
charges. Their exclusion from this study does not suggest that either the cost of
drugs to the elderly population is unimportant, or that it does not represent the
major cost burden for prescribed medication in EU countries, but rather that for
the purposes of this study their inclusion in the test scenarios would complicate and
‘distort’ the findings.
A limitation of the scenarios is that they do not incorporate any financial details,
such as gross income, disposable assets, or receipts of social or welfare benefits or
subsidies. These are important because prescription charges may be waived in
different countries, on the basis of low income or receipt of welfare benefits. The
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assumptions made in these scenarios are that such exemptions do not apply. The
assumption is also made that within the scenarios, patients are subject to standard
charges, and that they have not reached prescription charge ceilings, in countries
where they apply, e.g. Germany. The absence of an income dimension to the
scenarios means that exploration of the Dutch system was limited to its description,
since the cost of prescription medicines at or below the reference price, are not
shared with individuals below a certain income, and for those above, the co-pay-
ment system depends on the health insurance scheme purchased.
Although prescribing behaviour varies between individual physicians, and na-
tional prescribing patterns differ significantly, for the purposes of this study it is
necessary to exclude differences in costs arising from variations in prescribing
practices. Therefore the prescriptions within the scenarios are standardised and
based on contemporary UK therapeutic practice, and the products involved are
those licensed for use by the UK medicines regulatory authorities, and described in
the British National Formulary [15]. They include products prescribed by the brand
name of a particular manufacturer — and identified in the scenarios by inverted
commas — and those prescribed generically by their approved names.
Dispensing controls also vary across the countries included in the study. In many
countries, pharmacists are required to supply medicines in original packs and to
dispense the number that most closely covers the number of dose units prescribed,
whereas in UK, the exact number of dose units prescribed is dispensed. Some EU
countries limit prescribing and dispensing to branded products, e.g. France. Pack
sizes also vary between countries, as well as the available strengths of products.
Normal dispensing conventions in complying with prescribers’ instructions were
assumed in each of the respective countries.
The prices of the prescribed medicines were derived from the standard prices
listed in editions, current in July 1996, of appropriate publications in each country,
i.e. Index of Medicines — Main Association of the Austrian Social Security
(Austria); Drug Tariff (Finland); Red List of the Federal Association of Pharma-
ceutical Industry (Germany); OEMF, L’informatore Farmaceutico (Italy); NHS
List Price for branded products and Drug Tariff for generic products (UK).
No allowance was made for discounts on list prices in countries where these are
formally incorporated, e.g. Italy and UK, but the standard handling charge of 0.45
ecus was included in Finnish prices. For branded products, the medicine price used
in each country was that of the prescribed brand (or equivalent brand of the same
manufacturer) of the equivalent strength in the same dosage form, e.g. tablet,
pressured aerosol, etc; and identical or nearest equivalent pack size. For generic
prescriptions, the medicine price used was the price of the lowest cost product listed
of the approved drug name, of an equivalent strength in the same dosage form and
of the same or nearest equivalent pack size.
The patient charges were calculated by applying the prescription charge system
operated in the respective countries, to products and packs that would normally be
supplied by a dispensing pharmacist, in each country, in filling the prescriptions in
the scenarios.
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In the event, in 10 of the 20 scenarios developed, the products prescribed were
unavailable in more than two of the countries surveyed or there was sufficient
uncertainty about the comparability of products between countries for reliable
inclusion in the study. Details of the individual prescription scenarios included in
the study are provided in Appendix A.
The survey of medicine prices and patient costs, using the ten standard prescrip-
tion scenarios was undertaken in six of the countries in July 1996, and in Denmark,
in October 1996. The Netherlands was not surveyed for the reasons explained
above. The monetary values associated with prices and costs in each country were
converted to ecus (now euros), using exchange rates listed in the 16 October 1996
edition of The Financial Times. A comprehensive list of the prices of prescribed
medication associated with each of the scenarios is provided in Appendix B, and
similarly a comprehensive list of patient costs in given in Appendix C.
3. Cost sharing schemes for prescription medicines in Europe
Table 1 provides details of the main features of prescription charge systems in
eight EU member states. Three countries were included as examples of fixed price
systems, i.e. Austria, Germany, UK. The UK is the simplest and easiest to
administer, with a flat rate charge per item. Austria has a fixed rate per pack, and
therefore the patient co-payment burden depends on the number of packs dis-
pensed. Germany has three levels of co-payment depending on the pack sizes —
small, medium and large — and so the total co-payment payable is dependant on
the size of the packs and the number of each pack size dispensed. Three countries
— France, Denmark and Italy — have graduated systems, based on the designated
therapeutic status of individual products. In France patients pay, either 0, 35 or
65% of the cost of the prescribed products and in Denmark patients pay either 0,
25 or 50% of the cost of the medicines prescribed. Italy also has a graduated system
— 0, 50 and 100%, but other than for products in 100% band, a fixed prescription
charge per pack is also levied, similar to Austria. In Finland patients are normally
liable for the first 8.7 ecus of their prescription charge and refunded 50% of the cost
above this deductible. For patients with serious long-term illness, the deductible is
halved, and the refund is either 75 or 100% of the prescription cost. In the
Netherlands, prescription drugs are available under the public health system free of
charge providing their price does not exceed the reference price. In 1996, an average
of 0.6 ecus per public insured person was paid to cover the cost of prescription
drugs above the reference price system.
Alongside different systems of cost sharing, there is a diverse range of exemp-
tions. Exemption status may be gained from prescription charges or co-payments
on the basis of age, income, or clinical conditions. In some countries, the majority
of the population, are exempt. In UK, 85% of NHS prescription items — provided
to over half the population are exempt from charges on the grounds of age
(Scenario 5 and 9), income or clinical condition (Scenario 7). Extensive scope for


















Prescription charge arrangements within public health systems (July 1996)
Deductible Grounds forType of charge Refund:compensationCountry Patient charge Ceiling on patient
exemption(ecus) systemcharge
NoDisease state;NoAustria 3.15 per packFixed
low income
No0; 25; 50% of drug No For low incomeGraduated NoDenmarka
patients, throughcost
counties
8.7 ecus is standard 553 ecus in a year Low income patientsFinlandb 0, 25%; 50% ofGraduated above a
can apply for fulldeductible; adrug cost abovefixed cost deductible
refund throughdeductible of 4.35deductible
municipalityecus applies in seri-
ous long-term illness
No ‘Mutuelle’ comple-No 31 disease states;0; 35; 65% of drugGraduatedFrance
mentary coveragelow incomecost
Children up to 181.56, 2.60, 3.64 2% of incomeGermany Fixed No No
years; low income generally, but 1%depending on pack
for chronically illsize
patients
Italy 0, 50% of direct No Age; disability;Graduated plus fixed No No
disease state; lowcost plus 1.57 percharge
pack or full cost income
No charge for annual – –Zero unless drug –Netherlands –
price is above refer-income below 23 180
ecus ence price system,
when patient pays
difference
Through pre-pay-FixedUK Age, disease state,No No7.04 per item
ment certificate atlow income
cost of 100.35 ecus
annually
a October 1996.



















Range of drug prices and patient costs (1996) for prescribed medicationa
Prescription scenario Patient costsDrug price Comments
Min–max (ecus) Min–max (ecus)
3.62(UK)–11.03(D)b 1.56(D)–9.15(FL) German price the highest, but the lowest cost to the patient.Scenario 1
Finnish cost is highest to patient
1.20(F)–10.21(DK)Scenario 2 French, German patients pay the lowest; Danish, British pay the most.1.05(I)–10.21(DK)
Only case where Finnish are not one of the highest
0.71(UK)–25.96(D)Scenario 3 2.38(F)–9.68(FL) British patients pay one of the highest costs with the lowest price,
French Italian, German patients have the lowest costs
Scenario 4
Product not available in 2.60(D)–8.89(FL) German price the highest, but the lowest cost to the patient;4.20 (UK)–12.48(D)
highest cost to Finnish patients. British patients pay more than the priceFrance and Italy
2.76(UK)–22.0 FL) 0(UK)–8.77(FL) UK, French, Italian, German patients pay less. Finnish pay the highestScenario 5
1.57(I)–12.14(FL) Cost divergence much larger than price divergence.8.49(F)–16.80(A)Scenario 6
British patients do not benefit from lower prices
UK, French, Italian, German patients pay less. Austrian,0(UK)–13.54 (FL)Scenario 7 1.17(UK)–37.35(D)
Danish similar
Scenario 8 6.24(D)–22.06(DK)28.44 (F)–126.03(D) Germany highest price but lowest cost to the patient. Low price countries
do not benefit the consumer. Danish and Finnish patients pay the most
0(D:UK)–35.60(FL) Patients are exempt on grounds of age in Germany and UK.Scenario 9 33.32(I)–129.33(FL)
Patient cost low in Italy. Price of both products, and cost to patient highest in
Finland
a A, Austria; D, Germany; DK, Denmark; F, France; FL, Finland; I, Italy; UK, United Kingdom.
b In parenthesis, are given the symbols of the European countries where the price or the cost to the patient is the lowest (Minimum) or the highest
(Maximum) for the seven countries.
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exemption under 31 diseases, which require the prescriber’s declaration (e.g. Sce-
nario 10).
In Germany, exemptions can also be obtained on the basis of age (Scenario 9),
and income: less than 10 600 ecus for singles, 14 400 ecus for couples annually. In
Netherlands, there is no charge for prescribed medicines (costing no more than the
reference price) under the compulsory sick fund scheme for employees and families
who earn less than 23 180 ecus annually.
Several countries also have systems which cap the amount an individual has to
pay for prescribed medicines in a year: In Finland, this is 553 ecus, whereas in
Germany, total liability is limited to 2% of total income, and for chronically ill
patients, 1%. In UK, pre-payment certificates can be purchased for 4- and 12-
month periods, relieving holders of any further charges for prescriptions, regardless
of the amount of medicines prescribed.
For low income patients, both Denmark and Finland have schemes whereby the
costs of prescription medicines may be refunded by local municipal authorities.
In France, the cost burden of prescription co-payments is reduced through a
widespread system of complementary insurance coverage called ‘Mutuelles’, which
compensate the individual for costs associated with prescription medicines.
4. Results
Table 2 records the range of drug prices and patient costs for scenarios 1–9.
(Scenario 10 is analysed in more detail in Table 3.) For both ranges, it indicates the
Table 3
Drug prices and patient costs of quadruple therapy for post-infarct patient (Scenario 10)









Minimum list price (ecus) % of drug price borne by(b) Individual prescrip-
Meantion products Range patient
‘Capoten’ 17.3 (10.67–31.57) 0–58
0–2816Frusemide (0.25–7.78)4.1
32.4‘Zocor’ (23.41–40.39) 0–51
Acetysalicylic Acid 3.7 (2.41–4.83) 0–292
a Assuming all four items in the prescription were purchased at the same time. If they were purchased
individually the total cost would be 43.86 ecus.
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countries with the minimum and maximum values for each prescription scenario
and comment is provided on the comparable patient costs of each scenario in
different countries, and on any notable observations between drug cost and patient
charge.
There are wide divergences both in drug prices and patient costs for the selected
prescription scenarios (Table 2, Appendices B and C). For some scenarios, the price
divergence is larger than the cost divergence but in other cases the divergence in
patient cost is even larger than the price divergence. Countries with very high prices
— Germany is often listed as the highest priced country out of the seven — do not
necessarily translate into high cost countries for the consumer. On the contrary, in
several scenarios (e.g. 1 and 8) German prices are the highest but the costs to the
patient are the lowest.
British patients face in several scenarios (e.g. 1, 3 and 4) a very peculiar situation,
since the drug prices are the lowest of the seven countries, but the British patient
pays more than the price and sometimes amongst the highest prices.
4.1. The patient cost of comparable drug therapies
Scenarios 1 and 2 (Fig. 1a) relate to middle-aged women in regular employment
requiring medication for pain control — one for a sports injury and one for
migraine. Scenarios 3 and 4 (Fig. 1(b)) involve short courses of treatment for
infections in young women. Scenarios 5 and 6 (Fig. 1(c)) address long term drug
therapy requirements intended to prevent serious future morbidity, i.e. cardiovascu-
lar crises and osteoporosis.
Within these illustrative six scenarios, the patient cost of prescribed medication in
France, Germany and Italy is generally less than that in the other four countries,
except when exemptions come into play. In France and Italy the lower patient cost
is attributable to lower drug prices and in Germany because the co-payment is on
average a substantially smaller proportion of the drug price. Patient costs in
Finland are consistently higher than in other countries in the three sets of scenarios.
In countries with a fixed charge system (e.g. Austria, Germany and UK) patient
charges for comparable drug therapies are obviously more likely to be the same (see
Fig. 1) whereas in other countries the cost of drugs for similar conditions are
markedly different, since they reflect the prices of the prescribed products.
4.2. Multiple drug therapy
Scenario 10 — concerning a post-myocardial infarct patient — provided us with
an opportunity to explore the impact of patient charge systems on multiple drug
therapy in the individual patient. From a clinical viewpoint each product provides
a separate and necessary component of the contemporary drug management of
patients following a myocardial infarct. Each is important in preventing the
occurrence of a further ‘heart attack’ leading to further incapacity or death.
However only in Austria and UK is the cost to the patient for 1 month’s treatment
the same for each of the four drugs (Fig. 2). Table 3(a) demonstrates that there is
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Fig. 1. Cost to patient (ecus) of prescribed medication: (a) scenarios 1 and 2. (b) scenarios 3 and 4.
*Products in senario 4 not available in France or Italy. (c) scenarios 5 and 6. *within scenario 5, patients
are exempt from prescription charges in the UK. Data not available
a greater order of diversity of patient costs than drug prices for the full prescrip-
tion, and that patients in Finland and UK would bear the major share of the costs.
The greater diversity of costs over prices is in fact reflected in each of the
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components of the prescription (Table 3(b)), and in Italy and UK, the patient can
pay significantly more than the list price. (Low-dose aspirin has been included in
this scenario for illustrative purposes, and in UK at least, it is unlikely that patients
would actually pay a prescription charge for this item because they would normally
be advised to buy the product over-the counter from pharmacies, since the purchase
price is less than the prescription charge).
5. Discussion
5.1. Determining the impact of different pharmaceutical reimbursement policies
The investigation of the differential impact of cost-sharing systems on the uptake
of different therapeutic groups of prescription drugs is a recent development [4].
Policy-makers still rely on post-implementation surveys to determine the effect of
new pharmaceutical reimbursement schemes on patterns of consumption of pre-
scription medicines [13,14]. Ideally, models of cost-sharing schemes should be tested
before implementation, using an evaluation instrument encompassing drugs across
a wide therapeutic spectrum and patients in a variety of socio-economic circum-
stances. The approach adopted in this study of using patient scenarios, incorporat-
ing common clinical conditions and appropriate prescriptions, provides a start in
this direction.
In pursuing this approach, the following factors are helpful to note:
Choice of clinical conditions—these need to be selected to cover a variety of
well-defined conditions amenable to drug therapy, ranging from the self-limiting to
the incapacitating and life-threatening, and with a comparatively high prevelance
within the population under study.
Fig. 2. Cost ecus to post-myocardial infarct patient of multiple drug regimen (scenario 10). *Assuming
all 4 items were purchased simultaneously. Within this senario, patients were exempt from prescription
charges in France.
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Choice of prescribed regimens—these should represent evidenced-based, currently
recommended drug therapy derived from standard prescribing references and:or
condition-specific consensus guidelines. Only half of the original scenarios de-
vised for use in this current European study could in the event be used either
because of the unavailability of particular products in some countries or uncer-
tainty in the comparability of products. Therefore, in international studies it is
important to devise prescription scenarios based on an awareness of consump-
tion data of different brands, dosage forms and packs.
Socio-economic components of scenarios — scenarios need to incorporate a
variety of patient ages, social circumstances and clinical histories. The scenarios
in the present study were found wanting in their lack of detail on income,
economic circumstances and expenditure on prescription medicines.
Specifically designed batteries of scenarios could be devised to investigate the
impact of specific exemption criteria including for instance, the introduction of
charge ceilings, or to consider the impact of cost-sharing schemes on particular
social or disease groups.
5.2. Comparing costs and treatments
This study begins to explore the patient cost burden of comparable treatments
within different national pharmaceutical pricing and cost sharing schemes. We
have used the comparators of the treatment of acute infections and pain relief
and also considered the patient cost of long-term medication, using antihyperten-
sive and hormone replacement therapy (HRT) regimens as examples.
Fig. 1 confirms that the patient’s cost burden for prescription medicines is
consistently lower in some countries than in others. It also shows that patient
costs of comparable drug treatment regimens are more likely to be similar within
fixed charge systems.
Other recent studies [4,11] have considered both the importance of patient
income and type of therapy on the impact of patient charges on uptake of
prescribed medicines. A retrospective study of elderly beneficiaries of the Penn-
sylvania Medicare programme [4] demonstrated that not only were those with
the lowest income level least likely to medicate, but there was a significant
differential price elasticity across different therapeutic groups (presumably) based
on patients’ perceptions of therapeutic importance.
The significance of our findings in the context of these two studies is that
patients are likely to make decisions about paying for, and therefore using
prescribed medicines, on the basis of their own economic circumstances, the cost
burden of prescribed medication, and their judgement of the clinical benefit of
the individual drugs prescribed. Therefore, in a situation where composite drug
therapy is deemed clinically necessary (Fig. 2 and Table 3), patients in modest
financial circumstances may well be selective in the prescription drugs they use
on the basis of the cheapest and their — rather than the clinician’s —percep-
tion of the most important.
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5.3. Patient costs
This study does not pretend to draw clear conclusions about pharmaceutical
prices or patient charges for prescribed medicines in Europe since the number of
scenarios is very limited and is confined to seven countries. However this series of
case studies does provide a flavour of the complexity of European price structures
and the diversity of the impact of prescription drug reimbursement systems. In
some countries, the costs to patients of prescription medicines are consistently
cheaper, and in others generally higher (see Table 2 and Fig. 1). No account has
been taken in this study of the cultural factors relating to health care or its cost, or
of comparable average national incomes. Although these will have some bearing,
they do not affect the essence of these general observations on country-to-country
variation of prescription costs in the seven EU member states.
The cost to the patient of prescribed medicines in a graduated co-payment
scheme is a product of the drug cost, the co-payment banding and the designation
of therapeutic groups to co-payment bands. Therefore changes to either the drug
price control mechanism or to the patient co-payment system will affect the cost to
the patient. Within fixed charged schemes, the price to the patient of prescribed
medicines is independent of the drug cost, but the gearing between the two will be
of interest to health resource managers and policy-makers, if not directly to the
consumers.
Where the patient charge depends on the number of packs and:or size of the
packs, prescribing decisions are pivotal, since the patient cost depends on the
quantity prescribed and therefore the period of the prescription. In the graduated
percentage systems, the length of the prescription is immaterial to the cost burden
for long-term patients and, indeed, some countries (e.g. France and Italy) limit the
period of a prescription. However, in fixed charge systems, longer prescriptions are
likely to result in a lower cost burden for patients (e.g. in scenario 8 the UK patient
who received his medicines in monthly, rather than three-monthly, instalments
would pay three times the cost). Again in systems where a deductible is levied on
each prescription (rather than each medicine), costs are minimised by purchasing all
prescribed medicines together and for longer periods. There is a 24% difference in
the cost to Finnish patients in purchasing all prescribed medicines in Scenario 10
together, rather than individually.
5.4. Exemptions and refunds
Exemptions and refunds are on the one hand designed to avoid or attenuate the
barriers to necessary drug therapy that prescription charge systems impose. On the
other, they remove any brake on consumer demand and a significant constraint on
unnecessary access to medicines. In countries, such as UK, where non-prescription
medicines can be prescribed under the National Health service, exemption from
prescription charges provides a strong incentive to obtain them on prescription
rather than purchase them directly from the pharmacy and so incur the full cost
[16]. Therefore exemptions and refund systems, unless there are formulary or ‘Black
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List’ limitations, may lead to the national health system shouldering an unnecessary
burden of minor illness in terms of drug costs and professional time.
6. Policy implications of this study
Changes in prescription charges or reimbursement arrangements in EU countries
generally command extensive media coverage [17,18], but comment is usually
limited to policy considerations. What is important to patients, is the effect on the
cost of their prescriptions, and whether they can afford them. The use of patient
scenarios provides a method to study the impact of changes to cost-sharing
arrangements at the level of the individual patient, and a possible route to
evaluating models of pharmaceutical reimbursement prior to implementation.
The findings of this study have the following implications for policy formulation.
Evidence from earlier work [4,13] suggests that the diversity found in this study in
patients’ costs arising from treating the same or similar clinical conditions with
different prescribed medicines, may result in patterns of consumption at odds with
clinical need. A move towards convergence of patient costs, for comparable
therapies, could be achieved through a combination of a reference price system for
determining the price of drugs within therapeutic groups, such as currently exists in
Germany and the Netherlands, with patients’ contributions being determined by a
graduated co-payment scheme related to the therapeutic importance of the product,
such as currently exists in France.
A policy of generic prescribing within graduated co-payment schemes, would
reduce the cost burden on the patient and could significantly improve the uptake of
prescribed medicines, as well as achieve savings for the drugs bill.
With fixed charge schemes, policy limitations on the length of prescriptions may
significantly increase the cost of prescribed medication to patients with chronic
disorders.
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Appendix A. Prescription scenarios
1. A 42 year old female married teacher — who teaches history in a state-funded
school for girls aged 11–18 — sprained her ankle whilst playing tennis with
her neighbour outside of school hours. Her husband is a self-employed
architect. Prescription: ‘Synflex’ two twice daily after food. Supply sufficient
for 5 days.
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2. A 35 year old female bus driver suffers from migraine — averaging one attack
per month — for which she carries medication to use immediately at the onset
of an attack. Prescription: ‘Cafergot’ one or two at onset of attack and up to
two as required over the next 24 h. Supply 20.
3. A 23 year old single woman, who lives with her 2 year old daughter, in
municipal rented accommodation, and works part-time (15 h per week) as an
office cleaner has developed an acute chest infection for which she requires a
course of antibiotics. Prescription: Amoxycillin 250 mg three times daily. Send
sufficient for 5 days.
4. A 21 year old psychology undergraduate student who is attending a state
university and is financially supported by her parents, recognises from her
symptoms — which mimic those that she experienced once before 15 months
ago — that she has vaginal candidiasis, for which she requires treatment.
Prescription: ‘Canesten I’ to be used at night.
5. A 62 year old legal clerk, living with his second wife and three teenage
children, has been treated for hypertension for 5 years. Prescription: Atenolol
50 mg one daily for 2 months.
6. A 50 year old non-working grandmother who lives with her 54 year old
husband — who is an ex-psychiatric nurse who retired early two years ago —
requires hormone replacement therapy after having a hysterectomy 4 years
ago. Prescription: ‘Estraderm TTS 50’ one to be applied twice weekly. Supply
sufficient for 1 month.
7. A 28 year old housewife, married to a factory worker, has been diagnosed as
suffering from post-natal depression 10 weeks after the birth of her second
child- for which antidepressant therapy is required. Now 12 weeks post
partum, the dosage is being increased to a full therapeutic level. Prescription:
Imipramine 25 mg two three times daily. Supply sufficient for 4 weeks.
8. A 27 year old hospital porter lives with his partner — who is a medical records
clerk in the same hospital — their 3 month old son and her 3 year old son. The
patient was diagnosed as suffering from mild ulcerative colitis 9 months ago
for which he is now receiving routine maintenance therapy. Prescription:
Sulphasalazine 500 mg four times daily. Supply sufficient for 3 months.
9. An 18 year old schoolboy — whose father is a full-time swimming instructor
and coach, and mother is a part-time cashier at the local leisure centre —
suffers from exercise-induced asthma, i.e. Adult Step:2, which was diagnosed
10 years ago. He requires routine maintenance therapy. Prescription: (a)
‘Becotide-200’2. Two puffs twice daily. (b) Salbutamol inhaler. One–two
puffs before exercise.
10. A 53 year old divorced male executive is recovering at home after suffering a
myocardial infarct 4 weeks earlier. He is in the care of his daughter who is 25
years old, single and unemployed. Prescription: (a) ‘Capoten’ 12.5 mg twice
daily. (b) Frusemide 40 mg once daily. (c) ‘Zocor’ 10 mg one at night. (d)
Aspirin 75 mg two daily. Supply sufficient for 4 weeks.
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Appendix B. Minimum list prices of prescription ingredients (ecus)
Austria Denmark FinlandPrescrip- France Germany Italy UK
tion
Scenario
9.58 4.881 11.039.38 5.03 3.627.06
5.22 3.44 11.44 1.05 1.142 6.35 10.21
10.63 6.79 25.9611.71 7.653 0.7112.00
6.475.22 8.89 A 12.48 A 4.214
B16.50 22.00 11.49 19.00 12.52 2.765
15.57 8.49 16.7315.34 13.066 9.5416.80
7 27.14 18.36 10.10 37.35 9.01 1.1726.33
72.73 28.44 126.0387.20 43.168 29.0293.92
120.00 59.75 60.249a 29.4445.76 50.2069.45
9.33 4.70 11.494.70 3.889b 2.168.44
19.91 10.67 13.22 15.56 13.5210a 16.80 31.57
4.41 2.32 7.784.50 2.936.49 0.2510b
33.52 32.25 40.39 34.99 23.4110c 24.00 38.50
3.99 2.69 3.60 4.19 2.414.8310d 4.50
(A) Prescription product not marketed in France and Italy.
(B) Data unavailable.
Appendix C. Cost of prescriptions to patient (ecus)
Austria Denmark Finland France GermanyPrescrip- Italy UK
tion
scenario
3.15 3.55 9.15 1.71 1.56 1.57 7.041
3.15 10.21 5.22 1.20 1.56 2.62 7.042
9.68 2.38 2.605.88 3.143 7.046.30
3.15 3.62 8.89 A 2.60 A 7.044
8.77 4.02 4.16B 3.146.30 05
12.14 2.97 3.126 1.576.30 7.047.7
13.54 3.53 7.806.87 3.147 06.30








2.60 3.1410b 7.043.15 1.14
2.609.76 3.143.15 7.0410c
3.64 3.1410d 7.043.15 4.83
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